N-glycosylated insulin analogues

A pharmaceutical formulation comprising:

• (a) a multiplicity of glycosylated insulin or insulin analogues, each glycosylated insulin or insulin analogue having at least one N-glycan thereon, wherein the predominant N-glycan consists of a high mannose, hybrid, complex, or paucimannose N-glycan, and
• (b) a pharmaceutically acceptable carrier.

14-16. (canceled)

A method for altering a pharmacokinetic or pharmacodynamic property of an insulin or insulin analogue, comprising:

• attaching an N-glycan to an amino acid residue of the insulin or insulin analogue to produce a glycosylated insulin or insulin analogue, wherein the pharmacokinetic property of the glycosylated insulin or insulin analogue that is attached to the N-glycan is altered compared to the insulin or insulin analogue not attached to the N-glycan.

20-22. (canceled)

A method for producing an insulin or insulin analogue that has at least one pharmacokinetic or pharmacodynamic property sensitive to serum concentration of glucose when used in a treatment for diabetes, comprising:

• attaching an N-glycan to an amino acid residue of the insulin or insulin analogue to produce a glycosylated insulin or insulin analogue, wherein the glycosylated insulin or insulin analogue that is attached to the N-glycan has at least one pharmacokinetic or pharmacodynamic property of the insulin or insulin analogue that is attached to the N-glycan is sensitive to serum concentration of glucose.

-27. (canceled)

(canceled)